Align Technology, Inc., Aidite, Dental Doctor, WHOLE SHINE MEDICAL, Blue Sky Dental, among others, release financial reports; Aidite plans to make a special investment in Pute Medical; Dental Doctor …

# Align Technology 2026Q1: Revenue of $1.04 Billion, Global Clear Aligner Shipments of 685,700 Cases

On April 29, 2026, Align Technology released its financial results for the first quarter of fiscal year 2026. Quarterly revenue was $1.0401 billion, a year-over-year increase of 6.2%; GAAP net income was $112.8 million, up 21.0% year-over-year. Clear aligner shipments reached 685,700 cases, a year-over-year increase of 6.7%. By business segment, clear aligner revenue was $856.0 million, up 7.4% year-over-year; imaging systems and CAD/CAM services revenue was $184.1 million, up 0.9% year-over-year. The company announced it will initiate a $200 million stock repurchase program around May 1, 2026, expected to be completed within six months.

# Dental Doctor 2025 Annual Report: Revenue of RMB 1.767 Billion, Comprehensive Oral Service Revenue Up 37.15% Year-over-Year

In 2025, Dental Doctor Medical Holding Group Co., Ltd. achieved operating revenue of RMB 1.767 billion, a year-over-year increase of 12.14%; total profit was RMB 213 million, up 30.20% year-over-year; net profit attributable to shareholders of the parent company was RMB 137 million, up 26.97% year-over-year. Among this, comprehensive service project revenue was RMB 672 million, up 37.15% year-over-year; implant service project revenue was RMB 801 million, a slight decrease of 1.74% year-over-year; orthodontic service project revenue was RMB 294 million, up 8.68% year-over-year. As of the end of the reporting period, Dental Doctor operated 48 directly-owned institutions in the East China region, with revenue in Jiangsu Province reaching RMB 1.169 billion, accounting for 66.15%.

# Aidite 2025 Annual Report: Revenue of RMB 1.035 Billion, Overseas Market Revenue of RMB 686 Million

On April 29, 2026, Aidite released its 2025 annual report. Operating revenue reached RMB 1.035 billion, a year-over-year increase of 16.51%; net profit attributable to shareholders of the listed company was RMB 196 million, up 30.39% year-over-year. Overseas market revenue was RMB 686 million, up 24.90% year-over-year, with its share of total revenue rising from 61.85% to 66.31%. The first quarter of 2026 continued to grow, with revenue of RMB 257 million, up 25.35% year-over-year. Dental restoration material revenue was RMB 736 million, accounting for 71.16% of revenue. R&D expenditure reached RMB 73.5862 million, up 55.37% year-over-year. The company has established partnerships with multiple institutions to advance digital transformation and plans to set up an industrial fund to invest in orthodontic consumables company Pute Medical.

# Guangxi Lantian Stomatological Hospital 2025 Annual Report: Revenue of RMB 375 Million, Net Profit Up 124.24% Year-over-Year

On April 27, 2026, Guangxi Lantian Stomatological Hospital Group Co., Ltd. released its 2025 annual report. The company achieved total operating revenue of RMB 375 million, a year-over-year increase of 29.81%; net profit was RMB 11.9001 million, up 124.24% year-over-year. Net profit attributable to shareholders of the listed company was RMB 6.8995 million, up 261.32% year-over-year. The performance growth was mainly attributed to market demand recovery, improved patient acquisition capabilities at clinics, online and offline marketing promotions, and revenue and profit from the acquisition of Anhui Beijie Medical. The company completed the acquisition of a 55% equity stake in Beijie Medical, adding RMB 57.4513 million in revenue from the Anhui region, with a gross margin of 55.83%. As of the end of the reporting period, the company's total assets were RMB 468 million, total liabilities were RMB 241 million, and the debt-to-asset ratio was 51.50%.

# HILE 2025: Revenue of RMB 188 Million Triggers *ST, Goodwill Impairment Leads to Net Loss of RMB 311 Million

On April 30, 2026, HILE disclosed its 2025 annual report. Full-year revenue was RMB 188 million, a year-over-year decrease of 30.69%; net profit attributable to the parent company was a loss of RMB 311 million, down 281.93% year-over-year. The core reason for the swing from profit to loss was the provision for a large amount of goodwill impairment. Affected by macroeconomic fluctuations, industry policy adjustments, and intensified market competition, the performance of the acquired IVD platform Jiemen Biology and the oral restoration material platform Ruisheng Biology fell short of expectations. On the same day, the company's stock abbreviation was changed to "*ST HILE", and a delisting risk warning was implemented starting May 6, 2026. The net operating cash flow for 2025 was RMB 58.8327 million, with expectations of a gradual recovery in 2026.

# WHOLE SHINE MEDICAL 2025 Annual Report: Oral Medical Service Revenue Down 17.54% Year-over-Year, Delun Medical Net Profit Turns to Loss

In 2025, the net profit attributable to the parent company was a loss of RMB 119 million, with the loss expanding by 216.85% year-over-year. WHOLE SHINE MEDICAL TECHNOLOGY CO., LTD. released its 2025 annual report. Oral medical service revenue was RMB 638 million, a year-over-year decrease of 17.54%, accounting for 90.74% of total revenue. The net profit of its core subsidiary, Delun Medical, turned from a profit of RMB 45.8228 million to a loss of RMB 17.6013 million, mainly due to intensified market competition and rising patient acquisition costs, leading to a decline in average patient spending. The full-year loss was primarily concentrated in two non-cash asset impairments, totaling RMB 54.38 million, accounting for 43.19% of the annual loss. As of the end of 2025, Delun Medical operated 28 clinics across four cities: Guangzhou, Foshan, Zhaoqing, and Huizhou.

# Jiahong Dental 2025 Annual Report: Revenue of RMB 511 Million, Implant Product Revenue Down 16.71% Year-over-Year

On April 28, 2026, Jiahong Dental released its 2025 annual report. The report shows the company's revenue was RMB 511 million, a year-over-year decrease of 1.31%; net profit attributable to the parent company was RMB 46.3972 million, down 11.26% year-over-year. Implant product revenue was RMB 65.379 million, down 16.71% year-over-year, the main reason for the performance decline. Denture product revenue was RMB 435 million, up 1.96% year-over-year. Overseas revenue reached RMB 273 million, accounting for 54.48%, up 2.36% year-over-year; domestic revenue was RMB 228 million, down 4.62% year-over-year. To cope with tariff fluctuations, the company established six new overseas subsidiaries to optimize the supply chain. R&D investment was RMB 26.7867 million, accounting for 5.24% of operating revenue.

# Huachi Dental 2025 Annual Report: Revenue of RMB 201 Million Down 13.88%, Net Profit Attributable to Parent Up 84.35%

In 2025, Huachi Dental Hospital Investment Management Co., Ltd. achieved operating revenue of RMB 201 million, a year-over-year decrease of 13.88%; net profit attributable to shareholders of the listed company was RMB 15.9473 million, up 84.35% year-over-year. The company's administrative expenses fell to RMB 28.339 million, down 36.02% year-over-year; financial expenses fell to RMB 7.4895 million, down 42.77% year-over-year; selling expenses fell to RMB 29.302 million, down 12.16% year-over-year. Revenue from the three major projects of dental restoration, implants, and diagnosis and treatment all declined, with only the orthodontic project achieving positive growth. Net cash flow from operating activities was RMB 49.9385 million, down 16.52% year-over-year. As of the end of the reporting period, Huachi Dental had 26 controlled subsidiaries and a total of 532 employees.

# Shinva Medical 2025 Annual Report: Revenue of RMB 9.736 Billion, Medical Device Manufacturing Product Revenue of RMB 3.695 Billion

On April 30, 2026, Shandong Shinva Medical Instrument Co., Ltd. released its 2025 annual report. The company achieved operating revenue of RMB 9.736 billion, a year-over-year decrease of 2.84%; net profit attributable to shareholders of the listed company was RMB 526 million, down 23.90% year-over-year. The decline in profit was greater than the decline in revenue, mainly due to increased selling expenses and a decrease in interest income leading to higher financial expenses. Medical device manufacturing product revenue was RMB 3.695 billion, down 1.08% year-over-year. Overseas self-operated business achieved revenue of RMB 396 million, up 46.04% year-over-year. During the reporting period, the company's net cash flow was RMB 701 million, up 55.44% year-over-year. As of the time of writing, the company has completed the equity transfer of three non-core subsidiaries, concentrating resources on its core main business.

# BLT 2025 Annual Report: Revenue of RMB 1.852 Billion, Dental Laser Powder Bed Fusion Pure Titanium Powder Obtains Class III Medical Device Registration Certificate

On April 30, 2026, Xi'an BLT Additive Technology Co., Ltd. released its 2025 annual report. The report shows the company achieved operating revenue of RMB 1.852 billion, a year-over-year increase of 39.69%; net profit attributable to shareholders of the listed company was RMB 204 million, up 95.14% year-over-year. The company's total R&D investment in 2025 was RMB 242 million, accounting for 13.05% of operating revenue. In the dental field, BLT's self-developed "Dental Laser Powder Bed Fusion Pure Titanium Powder" has obtained the Class III Medical Device Registration Certificate approved by the National Medical Products Administration, marking significant progress in compliant application in the medical field. The company plans to distribute a cash dividend of RMB 0.82 (tax included) for every 10 shares held by all shareholders.

# HILE to Implement Delisting Risk Warning from May 6, Stock Abbreviation Changes to "*ST HILE"

On April 30, 2026, HILE issued an announcement stating that because the company's audited total profit and net profit for 2025 were both negative and operating revenue was below RMB 300 million, it triggered the delisting risk warning threshold of the Shanghai Stock Exchange. The company's stock will be suspended from trading for one day on April 30 and will implement a delisting risk warning starting May 6, with the stock abbreviation changing from "HILE" to "*ST HILE". The 2025 annual operating revenue was approximately RMB 188 million, with a net profit attributable to the parent company loss of RMB 311 million, and a non-recurring net profit attributable to the parent company loss of approximately RMB 616 million. The board of directors of HILE stated it will take active measures to strive for the removal of the warning, planning to continue increasing investment, promote the improvement of main business scale, and strive to break through the RMB 300 million revenue threshold. If the financial indicators for 2026 still trigger the delisting risk, the company's stock will face the risk of termination of listing.

# Dental Doctor Plans to Invest Up to RMB 200 Million to Add Approximately 5 Oral Institutions in East China and Build a Headquarters Hospital

On April 23, 2026, the board of directors of Dental Doctor Medical Holding Group reviewed and approved the 2026 annual external investment plan. It plans to add approximately 5 oral medical institutions in the East China region, with a total investment not exceeding RMB 100 million, expected to be formally established in 2026 and opened between 2026 and 2027. At the same time, it plans to continuously invest in the construction of the headquarters hospital through its wholly-owned subsidiary, with funds also not exceeding RMB 100 million, mainly used for hospital decoration, equipment procurement, talent introduction, and information construction. The headquarters hospital is expected to open in 2026, serving as the company's core platform for innovative R&D and diagnosis and treatment of complex diseases. As of the end of 2025, Dental Doctor had 48 directly-owned chain oral institutions in the East China region.

# Aidite Plans to Invest RMB 100 Million to Establish an Industrial Fund, Specifically Investing in Pute Medical

On April 24, 2026, Aidite jointly invested with professional investment institutions to establish an industrial fund, specifically investing in the oral orthodontic materials company Zhejiang Pute Medical Devices Co., Ltd. The total subscribed capital of the fund is RMB 201 million, of which Aidite plans to subscribe RMB 100 million with its own funds, accounting for 49.75% of the fund's total subscribed capital. Pute Medical is mainly engaged in the R&D, production, and sales of oral orthodontic materials, including products such as orthodontic brackets and oral implant materials. The fund's operating term is 6 years and is subject to the filing process with the Asset Management Association of China. Pute Medical had its application for termination of listing accepted for review in February 2026 to improve decision-making efficiency and reduce operating costs.

# Guangdong Jibo Medical: Plans to Acquire 51% Equity of Guangzhou Dihua Dental for RMB 408,000, with Performance Bet

On April 24, 2026, Guangdong Jibo Medical Group Co., Ltd. issued an announcement, planning to acquire 51% equity of Guangzhou Dihua Dental Clinic Co., Ltd. for RMB 408,000. According to the agreement, Guangzhou Dihua commits that within the five fiscal years from 2026 to 2030, the net profit achieved in each fiscal year shall not be less than RMB 160,000. If the performance target is not met in any commitment year, Jibo Medical has the right to require the seller to repurchase the equity or provide performance compensation. After the transaction is completed, Guangzhou Dihua will become a controlled subsidiary of Jibo Medical and be included in the consolidated financial statements. As of December 31, 2025, the audited total assets of Guangzhou Dihua were RMB 390,800, and the audited net assets were RMB -583,000. This transaction does not constitute a major asset重组 or related party transaction.

# US Dental DSO DCA Announces Debt Restructuring: Reduces Debt by Over $1.1 Billion, Secures $95 Million in New Financing

On April 24, 2026, Dental Care Alliance (DCA), a dental support organization based in Sarasota, Florida, USA, announced a strategic transaction with its existing lenders. It is expected to reduce debt by over $1.1 billion and secure $95 million in new financing. The transaction aims to enhance financial flexibility, support long-term growth, and provide funding for clinic operations, with existing debt maturities extended to 2031. DCA supports over 400 clinics across 24 states in the US, with an annual patient volume of over 3 million visits and a total workforce exceeding 5,250. The transaction is expected to be completed in the second quarter of 2026, subject to customary closing conditions.

# AI Automatically Detects Dental Caries and Gingival Recession, 3Shape Diagnostic Software Receives FDA Clearance

On April 28, 2026, 3Shape announced that its Dx diagnostic software received 510(k) clearance from the US FDA, allowing qualified dental professionals to use the software for oral diagnosis and assessment of tooth and gum changes in adult patients in US dental clinics. The Dx software is available in two versions. Dx Plus is an AI-assisted diagnostic version that can detect dental caries, plaque, tooth wear, and gingival recession, while Dx Standard is a manual tracking version supporting all TRIOS models except TRIOS Core. Since 2025, the Dx software has been sold and used clinically in multiple countries and regions.

# Guangdong Proposes to Regulate Surgical Assistance Operation Prices: Implant Oral 3D Guide Plate at RMB 1,033/Piece, Robot Assistance Up to 300% Surcharge

On April 24, 2026, the Guangdong Provincial Medical Security Bureau issued a public notice on the proposed regulation and integration of prices for 37 surgical and treatment assistance operation items, clarifying the maximum price limits for the province. In oral medical care, medical 3D guide plate printing is proposed at RMB 1,033/piece, 3D model printing at RMB 517/piece, and 3D modeling at RMB 300/time. For surgical robot assistance operation fees, the robotic arm assistance operation fee is surcharged at 50%-300% of the main surgery price, with the amount ranging from RMB 2,000 to RMB 27,000. Additionally, intraoperative microscopic imaging assistance operation fees are proposed at RMB 120 per tooth/per root canal, and micro-power assistance operation fees at RMB 170/time.

# Hailijia Dental Responds to Multiple Store Closures: Rapid Expansion Led to Tight Cash Flow, Refunds Difficult in Short Term

On April 25, 2026, the person in charge of Hailijia Dental responded on Fujian Comprehensive Channel's program "First Help Group" regarding the previous closure of stores in Quanzhou, Xiamen, and Fuzhou. They admitted that rapid expansion led to tight cash flow, making it difficult to provide centralized refunds in the short term, involving thousands of affected children and approximately RMB 30-40 million in prepaid treatment fees. The company plans to maintain normal operations at its Fuzhou Aixin Hai store, has established an online medical team to provide remote services, and is actively engaging with private medical institutions. It plans to add a new offline diagnosis and treatment site in the Gulou District to ensure that children currently undergoing treatment can complete their courses.

# KIT Develops Ceramic-Metal Co-Printing Technology, Potentially Expanding to Precision Medical Manufacturing Fields Like Dentistry

Recently, a team from the wbk Institute of Production Science at the Karlsruhe Institute of Technology (KIT) developed a universal binder system capable of combining different ceramic materials or ceramic and metal materials in a single manufacturing process. The technology is based on the vat photopolymerization process, printing layer by layer using a photosensitive material containing ceramic or metal particles, ensuring a stable connection between materials during the printing phase. The research team stated that the system has potential applications in aerospace, medical, and mechanical engineering fields, such as manufacturing customized bone and dental implants. Some companies have already introduced 3D printing technology in denture production to optimize costs and efficiency, significantly reducing operating costs.